Recent Updates
Recently added Catalysts
NGNE Positive Sentiment

Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress

Tuesday, October 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Neurogene Inc. has announced its participation in the ESGCT 33rd Annual Congress, where it will present new preclinical data for its NGN-401 gene therapy program targeting Rett syndrome. The congress is scheduled for October 27-30, 2026, in Hamburg, Germany. This presentation aims to showcase the key differentiators of NGN-401, emphasizing its potential impact on patients with rare neurological diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Neurogene is presenting at a prestigious international congress.
  • New preclinical data highlights advancements in NGN-401 for Rett syndrome.
  • Focus on life-changing genetic medicines for rare neurological diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~26 mo
Minimal dilution risk
Lead asset
NL-201
Phase 1 · Solid Tumor

Full Press Release Details

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will present data from its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. New preclinical data to be featured are aimed at addressing two import

Frequently Asked Questions

What is NGN-401?

NGN-401 is a gene therapy program developed by Neurogene for treating Rett syndrome.

When is the ESGCT 33rd Annual Congress?

The ESGCT 33rd Annual Congress will take place from October 27-30, 2026.

Where will the ESGCT Congress be held?

The ESGCT Congress will be held in Hamburg, Germany.

What will Neurogene present at the congress?

Neurogene will present new preclinical data for its NGN-401 gene therapy program.

ShareAdd on Google
Tags: NGNE Neurogene NGN-401 Rett syndrome gene therapy ESGCT
Last updated: Oct 20, 2026

Biotech snapshot

Cash runway
$225M liquidity · $8M/mo burn
~26 mo
Minimal dilution risk
Lead asset
NL-201Phase 1
Solid Tumor →